Flower City Capital’s Immuneering IMRX Stock Holding History

Flower City Capital’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$275K	Hold	55,029	–	–	0.12%	40
2026 Q1	$290K	Buy	55,029 +12,800	+30%	+$65.6K	0.15%	35
2025 Q4	$278K	Buy	42,229 +13,000	+44%	+$83.5K	0.14%	34
2025 Q3	$205K	Sell	29,229 -2,800	-9%	-$14.5K	0.11%	39
2025 Q2	$108K	Buy	+32,029	New	+$54.9K	0.06%	38

Other funds holding IMRX

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Berman McAleer Timonium, Maryland $864M AUM 22.02% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

FFN

Focus Financial Network Minneapolis, Minnesota $3.23B AUM 29.61% 1-Year Est. Return

Flower City Capital's IMRX Position: Q2 2026 in Review

Flower City Capital held its Immuneering (IMRX) position steady in Q2 2026 at 55,029 shares worth $275K. The position accounts for 0.12% of the portfolio, ranked #40.

Flower City Capital first reported a position in IMRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $290K in Q1 2026. 5 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Flower City Capital held 55,029 shares of Immuneering worth $275K as of Q2 2026.
Flower City Capital left its Immuneering share count unchanged in Q2 2026.
Immuneering made up 0.12% of Flower City Capital's portfolio in Q2 2026, its #40 holding.
Flower City Capital first reported a position in Immuneering in Q2 2025 and has held it in 5 quarters since.
Flower City Capital's Immuneering position peaked at $290K in Q1 2026.
5 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Flower City Capital's 13F filing for Q2 2026, filed 7 Jul 2026.